|Description||An orally active testosterone 5-alpha-reductase inhibitor. It is used as a surgical alternative for treatment of benign prostatic hyperplasia. [PubChem]|
|DrugBank||Primary Accession Number: DB01216|
|Type||Approved, Small Molecule|
|Indication||For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: Improve symptoms, reduce the risk of acute urinary retention, reduce the risk of the need for surgery including transurethral resection of the prostate.|
|Mechanism of Action||The mechanism of action of Finasteride is based on its preferential inhibition of Type II 5a-reductase, an intracellular enzyme that converts the androgen testosterone into DHT. Inhibition of Type II 5a-reductase blocks the peripheral conversion of testosterone to DHT, resulting in significant decreases in serum and tissue DHT concentrations.|
You need to load/activate the cURL extension (http://www.php.net/cURL).
|Protein Binding||Not available|